Dual-mode lateral flow immunoassay based on gold nanoparticle-fluorescent microsphere nanocomposites for sensitive CA-125 detection in ovarian cancer screening.

Published 06/06/2026

Research record: Dual-mode lateral flow immunoassay based on gold nanoparticle-fluorescent microsphere nanocomposites for sensitive CA-125 detection in ovarian cancer screening.

Published in Anal Chim Acta; first publication date 2026-06-06. PMID 42508911.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Read the original publication on PubMed

Talk to a Specialist Browse all insights

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-06-06

Updated

2026-10-20

Disclaimer

professional use

References